T he association between higher blood pressure (BP) and chronic kidney disease (CKD) has been well established. [1][2][3] In addition to average BP values, BP variability (BPV) may be associated with CKD.
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CKD are poorly defined. 9 Hemodynamic stress (eg, hemodynamic overload and instability) and metabolic abnormalities coexisting with higher BPV (eg, obesity and metabolic abnormalities) [12] [13] [14] may contribute to CKD incidence and progression. However, no studies have assessed whether long-term BPV is associated with incident CKD independent of other BP parameters (eg, mean BP, cumulative exposure to BP) and metabolic parameter changes during follow-up.
Using a large nationwide database of participants recruited from the national health check-up system in Japan, 15 we assessed whether long-term BPV during 3 years is associated with the development of CKD and whether the association is independent of mean or cumulative exposure to BP 13, 16 and metabolic parameter changes in those without CKD and without diabetes mellitus.
Methods

Study Population
This study was performed as a part of the prospective ongoing project, Design of the comprehensive healthcare system for CKD based on the individual risk assessment by Specific Health Checkups. We obtained data through July 2013 on 105 045 participants (mean age±SD, 62.1±7.6 years; 41.0% men) for whom information on demographic variables (ie, age and sex), baseline BP (BP levels plus whether antihypertensive drugs were prescribed), and baseline (2008) and follow-up (2011) kidney function (ie, estimated glomerular filtration rate [eGFR] and dipstick urine test results) were obtained. Among 105 045 participants, we excluded those with at least 1 missing BP measurement during follow-up (n=24 976) and any missing covariates at baseline, such as body mass index (BMI, n=3), smoking status (n=2410), and glucose (n=19 240) and lipid parameters (n=14).
The study was conducted according to the guidelines of the Declaration of Helsinki and the Ethical Guidelines for epidemiological research (December 1, 2008, Ministry of Education, Culture, Sports, Science and Technology and Ministry of Health, Labor and Welfare of Japan). Ethical approval from the respective institutional review boards was also granted.
BPV and Other Measurements
BP measurement was measured at each local medical institution according to the recommendations of the Japanese Ministry of Health, Labor, and Welfare (http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/info03a.html), by medical staff using a standard sphygmomanometer or an automated device on the right arm after the participants had rested for 5 minutes in a seated position. Hypertension was defined as systolic BP (SBP)/diastolic BP (DBP) ≥140/90 mm Hg or use of antihypertensive medication.
For the BPV index, we calculated SD (SD SBP and SD DBP ), coefficient of variation (CV SBP and CV DBP ), the maximum and minimum BP difference (MMD SBP and MMD DBP ), and average real variability (ARV SBP and ARV DBP ) across 4 visits; all of these measures have been used in previous studies of BPV. [4] [5] [6] [7] [8] [9] [10] [11] 17 ARV is the average absolute difference between successive BP measurements, and in contrast with SD and CV, it takes the order of the BP measurements into account. 17 Here, we only report BPV using SD and ARV because CV and MMD are strongly correlated with SD (r=0.97-0.99; both P<0.001; Table S1 ). We also calculated baseline BP (Y 0 ), mean BP from Y 0 to Y 3 (Y 0-3 ), and cumulative exposure to BP 13, 16 from Y 0 to Y 3 (Y 0-3 ; mm Hg×year) to use as adjusted variables (Figure 1 ).
Other measurement information (eg, questionnaires and blood samples) is described in the online-only Data Supplement.
Definition of Diabetes Mellitus and CKD
Diabetes mellitus was defined as a fasting glucose concentration of 126 mg/dL or higher, hemoglobin A1c 6.5% or higher, or selfreported use of antihyperglycemic drugs. Urinalysis by the dipstick method was performed on a single spot urine specimen collected in the early morning after overnight fasting. Urine dipstick results were interpreted by the medical staff in each local medical institution and recorded as (−), (+), (1+), (2+), and (3+). In Japan, it is a widely adopted policy of the Japanese Committee for Clinical Laboratory Standards (http://jccls.org/) that all urine dipstick tests should be manufactured so that a urine dipstick result of 1+ will correspond to a urinary protein level of 30 mg/dL. We defined proteinuria as 1+ or more. Serum creatinine was assayed by an enzymatic method. eGFR was estimated by the CKD-Epidemiology Collaboration equation for Japanese as follows . eGFR decline from Y 0 to Y 3 , was calculated as (eGFR at Y 3 − eGFR at Y 0 )×100/eGFR at Y 0 . We also examined rapid eGFR decline, defined as greater than or equal to −3 mL/min per 1.73 m 2 /y, which has been used previously as a cutoff that reflects 3× more rapid decrease than expected by normal aging.
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Statistical Analysis
All statistical analyses were performed with SPSS version 18.0 J software (SPSS, Chicago, IL). The associations between individual variables were calculated by Pearson correlation method. To show the distribution of BPV over all participants, the range of each BPV index was calculated by decile. Differences in the risk for developing diabetes mellitus and CKD at Y 3 were examined among BPV deciles and by age-, sex-, and baseline BP-adjusted logistic regression models. Differences in eGFR decline from Y 0 to Y 3 , calculated as (eGFR at Y 3 − eGFR at Y 0 )×100/eGFR at Y 0 , among the decile groups were assessed using analysis of covariance with adjustment for age, sex, and baseline BP.
Unadjusted and multivariable-adjusted logistic regression models were used to assess the association between BPV and risk for newonset diabetes mellitus/CKD at Y 3 . In the first step, we carried out unadjusted analyses (model 1). In the second step, we added demographic variables (ie, age at Y 0 and sex) as adjustment covariates (model 2). In the last step, we further adjusted for clinical characteristics at Y 0 (ie, BMI, smoking, fasting glucose and lipid parameters, eGFR, and use of antihypertensive drugs) plus BP at Y 0 (model 3) or mean BP from Y 0 to Y 3 (model 4). These covariates were selected because they have significant correlations with BPV (Table S2 and S3) . We also assessed whether the association between BPV and CKD was independent of newly developed diabetes mellitus at Y 3 or changes in glucose and lipid parameters (ie, follow-up values minus baseline values for each parameter) during follow-up. The renal outcome was assessed as proteinuria, eGFR<60 mL/min per 1.73 m 2 , and rapid eGFR decline (greater than −3 mL/min per 1.73 m 2 /y) separately. As a sensitivity analysis, we conducted the following: (1) logistic regression analyses excluding those who had interim onset (at Y 1 and Y 2 ) of CKD, (2) assessment of the effects of exposure to long-term BPV through Y 0 to Y 2 on renal function at Y 3 , and (3) analyses by sex and excluding hypertensive individuals and those who had taken antihypertensive drugs. Statistical significance was defined as a P<0.05 on 2-sided tests.
Results
Study Population
The included participants (n=58 402) were slightly older (mean age: 62.1 versus 61.7 years), lower mean SBP (128.9 versus 129.5 mm Hg), and eGFR (76.5 versus 76.9 mL/min per 1.73 m 2 ; all P<0.001) than those not included (Table S4) . For the current analysis, we further excluded those with CKD (n=5143) and diabetes mellitus (n=4672) at baseline. As a result, 48 587 participants were included. The mean and range of each BPV index stratified by deciles is shown in Table S5 . Tables S2 and S3 show the associations between each BPV index and clinical characteristics. Higher age, higher BMI, and glucose and lipid metabolic abnormalities were weakly associated with higher SD BP (r= −0.02 to 0.12) and ARV BP (r=−0.01 to 0.11; all P<0.05). Current smokers showed higher SD BP and ARV BP compared with noncurrent smokers. Men showed higher SD SBP , SD DBP , and ARV DBP compared with women.
At 3-year follow-up, 1502 participants (3.1% of the entire population) had developed diabetes mellitus, and 3076 participants (6.3% of the entire population) had developed CKD, defined as the presence of proteinuria (n=1196) or eGFR<60 mL/min per 1.73 m 2 (n=1976). Figure 2 and Figure S1 show the ORs and 95% confidence intervals for new-onset diabetes mellitus and CKD at Y 3 with adjustment for age, sex, and baseline BP in deciles of SD BP and ARV BP . Higher SD BP and ARV BP were associated with a higher risk for new-onset diabetes mellitus and CKD. Figure 2C shows that higher SD BP and ARV BP were associated with a greater decline in eGFR from Y 0 to Y 3 . Table S6 shows the results of the multivariable logistic regression models, which determined the associations of SD BP and ARV BP with risk for new-onset diabetes mellitus at Y 3 . Higher SD BP and ARV BP were associated with diabetes mellitus risk (model 1), and the associations remained significant after adjustments for demographic variables (model 2) and baseline clinical characteristics and BP at Y 0 (model 3) or mean BP (Y 0−3 ; model 4). (Table S9) .
Overall patterns in the associations between measures of BPV and CKD were similar between men and women (Table  S10) . When we excluded patients on antihypertensive drugs at Y 0 or Y 3 (n=15 826), the relations of SD BP and ARV BP with (Table S11 ). There were no significant interactions between measures of BPV and sex or antihypertensive drug use in association with CKD (all P=NS). When we excluded hypertensive individuals at Y 0 or Y 3 (n=24 634), the associations of SD SBP and ARV SBP with CKD remained significant (Table S12) .
There were 44 103 participants with eGFR and urine dipstick results obtained at Y 1 and Y 2 , and these results were within normal range (ie, eGFR ≥60 mL/min per 1.73 m 2 without proteinuria). Among them, the associations of SD BP and ARV BP with CKD risk remained significant (Table S13) . When BPV was calculated across 3 (Y 0−2 ) visits, the results were mostly similar (Table S14) .
Discussion
In this nationwide study of 48 587 Japanese without diabetes mellitus or CKD at baseline (mean age: 62 years), we suggested that higher annual visit-to-visit BPV during 3 years was associated with a higher risk of new-onset diabetes mellitus and CKD, independent of baseline clinical characteristics and mean BP or cumulative exposure to BP during follow-up. The association between higher BPV and new-onset CKD was independent of new-onset diabetes mellitus and metabolic profile changes during follow-up.
Compared with average BP, translating BPV to medical setting is more complicated. There are some clinical implications in this study: those exhibiting mean absolute SBP differences >15 mm Hg (ie, ARV SBP >15 mmHg) between successive annual BP measurements were at a 1.4-fold higher risk for new-onset CKD compared with those with ARV SBP <4 mmHg ( Figure 2 ) during the 3-year follow-up period. The OR for CKD risk associated with a 6-mm Hg increase in ARV SBP was 1.13 (Table 2 ); the effect size was similar to that of a 3-U increase in BMI (OR, 1.13). ARV BP , rather than SD BP or CV BP , has been reported to be a better predictor of cardiovascular outcomes, 10, 11, 17 but such evidence on renal outcomes is scarce. In this study, apparent differences between ARV BP and SD BP in relation to CKD were not found. BPV SBP , rather than BPV DBP , showed more consistent relations with CKD risk (Tables S10-S12). Identifying which long-term BPV indices best identify those at higher CKD risk, and assessing how different time intervals between BP measures and different BP measure techniques (eg, home BP) could influence the clinical relevance of long-term BPV to renal outcomes, are potential avenues for future research. 20 The biological mechanisms behind the association of longterm BPV with CKD remain uncertain. Higher BPV may lead to increased oscillatory shear stress to the vascular endothelium, potentially contributing to early atherosclerosis (eg, increased expression of adhesion molecules, pro-oxidant processes, and NO synthase reduction) more than steady blood flow. 21, 22 Some experimental data have suggested that higher BPV with unchanged average BP induced afferent and intralobular arteriole remodeling (eg, vascular smooth muscle cells proliferation and extracellular matrix deposition), and resultant patchy and focal sclerotic lesions consisting of glomerular and tubular atrophy and surrounding interstitial fibrosis. 23, 24 In this study, higher long-term BPV was associated with risk of both proteinuria (a marker of glomerular barrier and endothelial cell dysfunction) 25 and low eGFR (<60 mL/min per 1.73 m 2 , a marker of parenchymal damages within the kidney and ultimately an overall index of kidney function) or rapid eGFR decline (greater than or equal to −3 mL/min per 1.73 m 2 /y). 3, 26 Even in nonhypertensive individuals, higher SD SBP and ARV SBP , but not baseline visit SBP or cumulative exposure to SBP during follow-up, were associated with a higher risk for CKD (Table S12 ). This may indicate that higher BPV is an initiating factor precipitating kidney injury. Reverse causality, that is, kidney dysfunction preceding higher BPV, might also be a consideration. 9 However, the associations of long-term BPV with CKD remained significant in those who had not developed CKD at the interim time points (ie, Y 1 and Y 2 ; Table S13 ). In addition, when we focused on the effects of exposure to long-term BPV through Y 0 to Y 2 on renal function at Y 3 , avoiding the inclusion of late assessments of BP at the end of follow-up, which might already have been affected by kidney function or other comorbidities, the conclusions were similar (Table S14) .
Long-term BPV represents an overall indicator of response to the intrinsic physiological and metabolic changes and the cumulative burden of lifestyle, nutrition, and other environmental stimuli.
9-11 Therefore, long-term BPV may merely be an epiphenomenon of certain pathophysiological conditions, such as abnormal neurohumoral function (eg, abnormal reninangiotensin system function or sympathetic nerve activity) and arterial stiffness. [9] [10] [11] The previous studies assessing longitudinal associations of long-term BPV with kidney dysfunction were conducted in patients with diabetes mellitus or CKD; most of them were taking antihypertensive/antihyperglycemic drugs, and comorbidities (eg, diabetic complications) were not uncommon. [4] [5] [6] [7] 9 Thus, the design of this study, excluding those with diabetes mellitus and CKD at baseline, minimized the potential problems of confounding. Metabolic abnormalities accompanying by higher long-term BPV 12-14 might be another confounder in previous BPV-CKD research.
4-7, 9 We found The major strengths of this study are its nationwide scope, large sample size, identical numbers of and equal intervals between BP measurements for each individual, and the incorporation of complete eGFR and proteinuria information at both baseline and follow-up. However, there were limitations. First, single measurements of BP, eGFR, or proteinuria might not be accurate, which could have led to underestimation of the true association between BP and CKD. Second, majority of people from the original cohort were not included in this analysis (54%). There is a potential bias in this study: lower SBP at Y 0 , lower average BMI, and a smaller proportion of current smokers in the included participants compared with the excluded participants might have led to underestimation of the true association between long-term BPV and CKD. Also, we could not assess what classes of antihypertensive drugs had been prescribed in treated hypertensive subjects. Some classes (eg, renin-angiotensin-aldosterone inhibitors and calcium channel blockers) might affect long-term BPV or kidney function, 29,30 although our conclusions remained unchanged with the exclusion of participants on antihypertensive medications during follow-up. Third, we have no information as to whether participants returned to the same laboratory for all their tests, and whether laboratories changed their methods or calibration during the time period. These factors could have introduced some measurement error. Finally, our sample consisted of middle-aged and older Japanese; thus our findings cannot be generalized to other race/ethnic groups.
Perspective
This Japanese nationwide survey demonstrated that, during 3 years of follow-up, those exhibiting higher long-term BPV were at higher risk for new-onset CKD. Our results emphasize the importance of focusing not only on BP values alone but also on visit-to-visit BPV to identify those who may be at risk for developing CKD in the future. Replication in different studies/cohorts is warranted. CKD is often asymptomatic but progressive, and thus we need to pay attention to those who have higher long-term BPV to detect CKD as early as possible and to prevent its adverse consequences, such as CVD and end-stage renal disease. What Is New?
Sources of Funding
• Higher long-term blood pressure variability in middle-aged and older adults without diabetes mellitus is associated with new-onset chronic kidney disease risk.
What Is Relevant?
• Longitudinal associations between long-term blood pressure variability and renal outcomes have been reported in populations with diabetes mellitus or chronic kidney disease.
• The effects of long-term blood pressure variability among individuals without diabetes mellitus on new-onset chronic kidney disease remain uncertain.
Summary
Among those in the middle-aged and elderly general population without diabetes mellitus, long-term blood pressure variability during 3 years was associated with new-onset chronic kidney disease risk, independently of mean blood pressure or cumulative exposure to blood pressure and metabolic profile changes during follow-up. value calculated with the following formula: HbAlc (%) = HbAlc (Japan Diabetes Society) (%) +0.4%. 4 Diabetes was defined as a fasting glucose concentration of 126 mg/dL or higher, HbA1c 6.5% or higher, or self-reported use of antihyperglycemic drugs.
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Supplementary Table   Table S1 . SBP indicates systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease. SD indicates standard deviation; ARV, average real variability; OR, odds ratio; CI, confidence interval. Statistical significance was defined as P <0.05. *P<0.05; † P<0.01; ‡ P<0.001. ※ SBP was used when the variables were SD SBP or ARV SBP , and DBP was used when the variables were SD DBP or ARV DBP.
SD indicates standard deviation; ARV, average real variability. Statistical significance was defined as P <0.05. *P<0.05; † P<0.01; ‡ P<0.001. Figure S1 Figure Legends Statistical significance was defined as P <0.05.
Supplementary Figure
